Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Organisation › Details

Catalym GmbH

CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn “cold” tumors “hot” and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1/-PD-L1 checkpoint inhibitors. The company’s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in H2 2020. The Company was founded with initial investments from Forbion and BGV in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg based on the innovative research work of Prof. Dr. Joerg Wischhusen. CatalYm is led by a seasoned senior executive team with substantial IO drug development as well as deal making experience and backed by international venture capital investors. CatalYm also received financial support from the EIF via the EIB-EIF Co-investment Facility, backed by the European Union through the European Fund for Strategic Investments (EFSI). *

 

Period Start 2016-08-03 established
  Predecessor University of Würzburg
Product Industry cancer immunotherapy (immuno-oncology, I-O)
Persons Person Rüdiger, Manfred (Catalym 202011 CEO formerly Affectis + Kiadis Pharma + Venture Partner LSP Munich)
  Person 2 Burger, Anne (MedVenture Partners 2002– Director + Breath Therapeutics 201609– CFO + Curetis 201007–2012 CFO)
     
Region Region München (Munich)
  Country Germany
  Street 19 Am Klopferspitz
  City 82152 Martinsried
  Tel +49-89-2000-664-40
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Catalym GmbH. (11/10/20). "Press Release: Catalym Raises EUR50 Million to Advance GDF-15 Antibody into Clinical Trials for Checkpoint-inhibitor Refractory Patients". Munich.
     
   
Record changed: 2020-11-15

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Catalym GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top